Suppr超能文献

用于靶向蛋白质降解的新型硅基疏水标签(SiHyT)的开发。

Development of Novel Silicon-Based Hydrophobic Tags (SiHyT) for Targeted Proteins Degradation.

作者信息

Ma Lan, Zhang Kun, Huang Ziqi, Guo Yuda, Liu Ning, Chen Jia, Wang Xinyue, Liu Ying, Li Mei, Li Jinxiao, Yang Cheng, Liu Shuangwei, Yang Guang

机构信息

The State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China.

出版信息

J Med Chem. 2024 Dec 12;67(23):21344-21363. doi: 10.1021/acs.jmedchem.4c02273. Epub 2024 Dec 2.

Abstract

Recent advances in targeted protein degradation (TPD) have propelled it to the forefront of small molecular drug discovery. Among these, hydrophobic tagging (HyT) strategies have garnered significant interest. Carbon-based hydrophobic tags have been recognized as effective Hyts for degrading a variety of target proteins. In this study, we introduce a novel class of potential EGFR degraders for the first time, which combine Gefitinib with silicon-based hydrophobic tags (SiHyT). The most promising candidate, degrader , which links Gefitinib to a simple TBDPS silyl ether, has shown efficacy in degrading mutant EGFRs via the ubiquitin-proteosome system (UPS) both in vitro and in vivo. Notably, degrader exhibits enhanced oral bioavailability owing to its superior metabolic stability compared to traditional carbon-based Hyts. Mechanistically, it was revealed that degrader disrupts EGFR stability by dissociating the EGFR-HSP90 complex and recruiting E3 ligase, RNF149. More importantly, the potent and selective PD-L1 and BTK degraders were discovered successfully by utilizing the SiHyT strategy. The development of these innovative SiHyT compounds could broaden the repertoire of HyTs, enhancing the future design of TPD agents.

摘要

靶向蛋白降解(TPD)领域的最新进展已将其推向小分子药物发现的前沿。其中,疏水标签(HyT)策略引起了广泛关注。碳基疏水标签已被认为是降解多种靶蛋白的有效HyT。在本研究中,我们首次引入了一类新型的潜在表皮生长因子受体(EGFR)降解剂,它将吉非替尼与硅基疏水标签(SiHyT)相结合。最有前景的候选物,即降解剂,它将吉非替尼与一个简单的叔丁基二苯基硅烷基醚连接起来,已在体外和体内通过泛素-蛋白酶体系统(UPS)显示出降解突变型EGFR的功效。值得注意的是,与传统的碳基HyT相比,降解剂因其卓越的代谢稳定性而表现出更高的口服生物利用度。从机制上讲,已揭示降解剂通过解离EGFR-热休克蛋白90(HSP90)复合物并招募E3连接酶RNF149来破坏EGFR的稳定性。更重要的是,通过利用SiHyT策略成功发现了强效且选择性的程序性死亡配体1(PD-L1)和布鲁顿酪氨酸激酶(BTK)降解剂。这些创新的SiHyT化合物的开发可以拓宽HyT的种类,增强未来TPD药物的设计。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验